



Exelixis Elects Jacqueline Wright to Its Board of Directors

December 17, 2021

-- Ms. Wright has decades of private and public sector technology experience including time at Microsoft, BP, General Electric and the UK government --

ALAMEDA, Calif.--(BUSINESS WIRE)--Dec. 17, 2021-- [Exelixis, Inc.](#) (Nasdaq: EXEL) today announced that accomplished technology executive Jacqueline (Jacky) Wright has been elected to the company's Board of Directors. Ms. Wright's appointment took effect on December 16, 2021.

Ms. Wright has decades of technology experience and is widely recognized for her expertise in digital transformation, both in the public and private sectors. She currently serves as Corporate Vice President & Chief Digital Officer, U.S. Business at Microsoft Corporation, which she joined as a Vice President, IT Strategic Enterprise Services in 2011. From 2017 to 2019, Ms. Wright took leave from Microsoft to serve as Chief Information & Digital Officer at HM Revenue and Customs, the United Kingdom's tax department, where she led digital transformation efforts preparing the department for the UK's departure from the European Union. Prior to joining Microsoft, from 2008 to 2011 Ms. Wright served as Vice President & Chief Information Officer, Corporate Functions at BP plc, the multinational energy company. Earlier in her career, Ms. Wright served in Chief Information Officer roles in multiple business segments of General Electric Company and also spent time at Anderson Consulting LLP and Ryder System, Inc., a leader in transportation and logistics.

"With extensive leadership experience at some of the world's top technology, energy and financial organizations, Jacky will be an invaluable addition to our Board of Directors," said Stelios Papadopoulos, Ph.D., an Exelixis co-founder and chairman of the company's board. "As Exelixis affirms its position as an oncology biotech leader, Jacky's growth-minded outlook and expertise in digital transformation will be highly beneficial for the company as it grows and scales."

"Exelixis has a proven track record of success in drug discovery, development and commercialization, and I am excited to be joining the company's Board of Directors at such an important time," said Jacky Wright. "I look forward to applying my experience and industry relationships to help the Exelixis team grow and execute on its mission of helping cancer patients recover stronger and live longer."

Ms. Wright is a current member of the industry advisory board at the Institute of Coding as well as a member of the data analytics advisory board at Bernard M. Baruch College, City University of New York, where she received her B.B.A. in Computer Information Systems & Accounting. Ms. Wright has also served as a board member for nVent Electric plc, a publicly held provider of electrical connection and protection solutions, since March 2020, and for Russell Reynolds Associates, Inc., a privately held global leadership advisory and search firm, since June 2021. She previously served on the board of trustees of Harvey Mudd College.

About Exelixis

Founded in 1994, Exelixis, Inc. (Nasdaq: EXEL) is a commercially successful, oncology-focused biotechnology company that strives to accelerate the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Following early work in model system genetics, we established a broad drug discovery and development platform that has served as the foundation for our continued efforts to bring new cancer therapies to patients in need. Our discovery efforts have resulted in four commercially available products, CABOMETYX® (cabozantinib), COMETRIQ® (cabozantinib), COTELLIC® (cobimetinib) and MINNEBRO® (esaxerenone), and we have entered into partnerships with leading pharmaceutical companies to bring these important medicines to patients worldwide. Supported by revenues from our marketed products and collaborations, we are committed to prudently reinvesting in our business to maximize the potential of our pipeline. We are supplementing our existing therapeutic assets with targeted business development activities and internal drug discovery — all to deliver the next generation of Exelixis medicines and help patients recover stronger and live longer. Exelixis is a member of the Standard & Poor's (S&P) MidCap 400 index, which measures the performance of profitable mid-sized companies. For more information about Exelixis, please visit www.exelixis.com, follow @ExelixisInc on Twitter or like [Exelixis, Inc.](#) on Facebook.

Exelixis, the Exelixis logo, CABOMETYX, COMETRIQ and COTELLIC are registered U.S. trademarks of Exelixis. MINNEBRO is a registered trademark of Daiichi Sankyo Company, Limited.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20211217005072/en): [https://www.businesswire.com/news/home/20211217005072/en/](https://www.businesswire.com/news/home/20211217005072/en)

Investors Contact:

Susan Hubbard
EVP, Public Affairs and
Investor Relations
Exelixis, Inc.
(650) 837-8194
shubbard@exelixis.com

Exelixis Media Contact:

Hal Mackins
For Exelixis, Inc.
(415) 994-0040

hal@torchcommunications.com

Source: Exelixis, Inc.